Farmas USA

Gracias. Me esperaré si llega a esa alcista, o cerca de ella. Pero me gusta para meter poco, si cbias el statu quo.

Asi que si se acerca y entonces tengo liquidez...ya veremos.

off
BABA
fuera en verde 93.33 escasos profits, no me fio

NVAX nota bioinvest

Tengo ya el doc completo  lo subire este finde

Confirmo que NO han vendido, siguen teniendo a NVAX en su portfolio.

HZNP breakout, se nota el calor de esa fase 3 que va a llegar en nada ... vamos a ver si cierra por encima de 20

GILD, las mas debiles se van a cerrar su gap las primeras ... 

NOTA ESPECIAL DE BIOINVEST POST-ELECCIONES - 9 Noviembre

Breaking News

The Biotech Sector BioInvest News – Biotech Sector – Trump Victory Brings V-Shaped Reaction – The immediate reaction of a widely unexpected Republican sweep was a huge across the board rally in health care stocks. While it is still very early to make definitive conclusions, several positive impacts have resulted in a major reversal of sentiment. Today’s impressive rally (NBI +9%) is a likelihood of some combination of the following macro fundamental and technical changes that are expected to occur with a new, right leaning administration. In a sector that has been painfully beaten down repeatedly since the original Hillary tweet in September 2015, the clouds are lifting. It may just be the beginning of a new regime although at the end of the day, as we know the best outcome is often statistically significant clinical trials that lead to commercially successful, life improving and/or saving, new drugs. Just like we were stuck over the past 15 months ago, these too are unchartered waters, only this time in the right direction.

Conclusion – The Perfect Storm In Reverse – The level of anxiety for the future of the biopharmaceutical sector peaked in October and early November, and the Trump victory has resulted in a major reversal of fortune in a broadly positive way. There are still many issues to be resolved with drug pricing, the overall cost of health care, changes to ObamaCare, etc. Nonetheless, the sharply improved sentiment is a welcome change and likely to create a more constructive investment landscape for biotech stocks going forward.

----------------------------------

Creo que nada de lo que dice esta gente se nos ha escapado a nosotros de comentar esta semana. Deberiamos tener nuestras propia "letter" ja,ja

IBB -2 ... esta se veia venir de ayer, la proxima semana creo que va a ser dura ...

dejo niveles y retrocesos ...

El dolar he perdido los 1,085 ... 

ADXS

Advaxis to Present Phase 1 Combination Data and New Preclinical Data Using AXAL at Upcoming Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting

http://finance.yahoo.com/news/advaxis-present-phase-1-combination-123000192.html